Tuesday, June 9, 2020, 5:00 PM – 6:30 PM

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from PracticeA Complimentary CNE (NCPD) Live Webinar Series

Gynecologic Cancers

Register Today for This CNE (NCPD) Virtual Event — 1.5 Credit Hours Available

Live Webinar

Join Us on Tuesday, June 9
5:00 PM – 6:30 PM ET

Complimentary Registration
A link to the event will be provided after registration.


Paula J Anastasia, RN, MN, AOCN
Gyn-Oncology Clinical Nurse Specialist
UCLA Medical Center
David Geffen School of Medicine
Los Angeles, California

Jennifer Filipi, MSN, FNP-C
Nurse Practitioner
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

David M O’Malley, MD
Division Director, Gynecologic Oncology
Gynecologic Oncology Phase I Program
The Ohio State University and
The James Cancer Center
Columbus, Ohio

Shannon N Westin, MD, MPH
Associate Professor
Director, Early Drug Development
Department of Gynecologic Oncology
and Reproductive Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas


Neil Love, MD
Research To Practice
Miami, Florida

Topics for Discussion

  • Module 1: Current Approaches to the Treatment of Newly Diagnosed Ovarian Cancer
  • Module 2: Emerging Concepts in the Management of Newly Diagnosed Ovarian Cancer
  • Module 3: Clinical and Practical Utilization of PARP Inhibitors for Recurrent/Relapsed Ovarian Cancer
  • Module 4: Current and Emerging Strategies for Metastatic Endometrial Cancer
  • Module 5: Optimal Treatment Approaches for Metastatic Cervical Cancer
A detailed agenda will be made available in the coming weeks.

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of gynecologic cancers.

Learning Objectives and Goals
Upon completion of this activity, participants should be able to:

  • Apply available research data to the therapeutic and supportive care of patients with ovarian (OC), cervical (CC) and endometrial cancer (EC).
  • Recognize the FDA approval of olaparib as maintenance therapy after first-line platinum-based chemotherapy for patients with advanced OC and a deleterious or suspected deleterious BRCA germline or somatic mutation, and consider how the availability of this strategy affects current therapeutic algorithms.
  • Review emerging trial data evaluating the use of niraparib as maintenance therapy in the first-line setting for patients with or without BRCA mutations, and consider the potential clinical and research implications of these findings.
  • Appreciate the biologic rationale for and available and emerging data with the use of PARP inhibitors in combination with antiangiogenic agents, and discern how this therapeutic strategy may affect therapeutic algorithms in the near future.
  • Recall available clinical trial data with FDA-approved PARP inhibitors for patients with OC in different disease settings, and safely integrate these agents into routine clinical care.
  • Appreciate the toxicities associated with PARP inhibitors commonly used in the care of patients with OC, and offer supportive management strategies to minimize and/or ameliorate these side effects.
  • Review published research data documenting the efficacy of anti-PD-1 monotherapy for patients with PD-L1 positive metastatic CC (mCC) who experienced disease progression on or after chemotherapy, and utilize this information to educate appropriate individuals about the potential benefits of this approach.
  • Consider available research data demonstrating the efficacy of anti-PD-1/PD-L1 antibodies for patients with and without microsatellite instability (MSI)-high EC, and identify individuals who may be eligible for this strategy within or outside of a protocol setting.
  • Evaluate the recent FDA approval of pembrolizumab in combination with lenvatinib for patients with advanced EC that is not MSI-high or mismatch repair deficient and who have experienced disease progression following prior systemic therapy in order to determine how to optimally integrate this novel regimen into current treatment algorithms.
  • Describe the biologic rationale for, published research data with, and ongoing evaluation of the use of immune checkpoint inhibitors in combination with chemotherapy, other immunotherapies and targeted treatments in the management of OC, EC and CC, and effectively prioritize clinical trial opportunities for eligible patients.
  • Recall the mechanisms of action of, emerging efficacy data with and toxicity profiles of novel targeted agents under investigation in OC, CC and EC.
  • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with OC, CC and EC to optimize clinical and quality-of-life outcomes.
Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form, which will be emailed to attendees after the event.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This activity will be submitted to the ONCC for ILNA verification.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE (NCPD) activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

RTP CNE (NCPD) planning committee members, staff and reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc and Merck.